COVID-19: Study shows five-day course of remdesivir works as well as 10-day one

0
0

Gilead Sciences, which has suggested that a shorter treatment duration could extend limited supplies of its drug remdesivir, on Wednesday published results of a study showing no significant difference in outcomes between 5- and 10-day courses of the drug for patients with severe COVID-19. Gilead announced “top-line” findings from the trial on April 29.

NO COMMENTS